Virus-associated chronic endometritis: treatment options
Authors:
- Natalia I. TapilskayaNTNatalia I. Tapilskaya
- Gulrukhsor Kh. TolibovaGTGulrukhsor Kh. Tolibova
- Tatiana G. TralTTTatiana G. Tral
- Alevtina M. SavichevaAlevtina M. Savicheva
- Ruslan I. GlushakovRGRuslan I. Glushakov
- Olga V. BudilovskayaOBOlga V. Budilovskaya
- Anna A. KrysanovaAKAnna A. Krysanova
- Alexander M. GzgzyanAGAlexander M. Gzgzyan
- Olesya N. BespalovaOBOlesya N. Bespalova
Open Access
- 30 November 2022
- journal article
- research article
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 24 (5) , 348-354
Abstract
Aim. To evaluate the effectiveness of Alloferon (Allokin-alfa) in the complex treatment of virus-associated chronic endometritis (CE) in patients with infertility, papillomavirus infection (PVI) persisting in the uterine cavity, and recurrent herpes-virus infection localized in the genital area. Materials and methods. A prospective (n=33) open randomized (2:1) study was conducted to assess the efficacy of Alloferon (Allokin-alfa) in the complex treatment of CE in patients with infertility, PVI, and recurrent herpes-virus infection, aged 25 to 37 years (median age 31 [29; 32.5] years). All patients received valacyclovir therapy at 500 mg once daily for 30 days from the day of randomization. Patients in the main group (n=21) simultaneously with the start of antiviral therapy received Allokin-alfa as 9 subcutaneous injections once every two days (one injection every other day). The uterine cavity microbiota of the patients was assessed 3 months after treatment, and histological and immunohistochemical studies of endometrial biopsy specimens were performed. Results. The microbiological data analysis showed HPV elimination in 71.4% vs 16.7% of patients in the alloferon and control groups, respectively (2 7.102, p=0.008). Also, in the main group, a significant decrease in the severity of CE (2 27.586, p0.001) and p16ink4a protein expression levels (2 6.17, p=0.013) were observed. Conclusion. In the treatment of virus-associated CE, the addition of alloferon to virus-suppressive therapy leads to higher rates of HPV elimination from the uterine cavity and significantly reduces the severity of CE.Keywords
This publication has 13 references indexed in Scilit:
- Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infectionInfectious Agents and Cancer, 2021
- Persistent human papillomavirus infection in the genesis of reproductive losses. Prospects for therapyMeditsinskiy sovet = Medical Council, 2021
- Is HPV the Novel Target in Male Idiopathic Infertility? A Systematic Review of the LiteratureFrontiers in Endocrinology, 2021
- Recurrent implantation failure – an overview of current researchGynecological Endocrinology, 2021
- The effects of human immunodeficiency virus, human papillomavirus, herpes simplex virus-1 and -2, human herpesvirus-6 and -8, cytomegalovirus, and hepatitis B and C virus on female fertility and pregnancyBritish Journal of Biomedical Science, 2020
- Еndometrial microbiota of women with chronic endometritis and idiopathic infertilityAkusherstvo i ginekologiia, 2020
- Human papillomavirus infection and female infertility: a systematic review and meta-analysisReproductive BioMedicine Online, 2020
- Chronic Endometritis: Old Problem, Novel Insights and Future Challenges2020
- The interaction between human papillomavirus and other virusesVirus Research, 2017
- Spontaneous clearance of the human papilloma virus as a result of suppressive therapy with acyclic nucleosides of a recurrent herpes-viral infectionGYNECOLOGY, 2017